nodes	percent_of_prediction	percent_of_DWPC	metapath
Vigabatrin—GABBR1—prostate gland—prostate cancer	0.0199	0.125	CbGeAlD
Vigabatrin—GABBR1—seminal vesicle—prostate cancer	0.0168	0.105	CbGeAlD
Vigabatrin—SLC36A1—prostate gland—prostate cancer	0.0156	0.0979	CbGeAlD
Vigabatrin—ABAT—prostate gland—prostate cancer	0.0155	0.0973	CbGeAlD
Vigabatrin—GABBR1—urethra—prostate cancer	0.0133	0.0835	CbGeAlD
Vigabatrin—SLC36A1—renal system—prostate cancer	0.0106	0.0668	CbGeAlD
Vigabatrin—ABAT—renal system—prostate cancer	0.0106	0.0663	CbGeAlD
Vigabatrin—GABBR1—bone marrow—prostate cancer	0.0102	0.0643	CbGeAlD
Vigabatrin—L-Glutamine—QARS—prostate cancer	0.00994	1	CrCbGaD
Vigabatrin—GABBR1—testis—prostate cancer	0.00875	0.0549	CbGeAlD
Vigabatrin—SLC36A1—bone marrow—prostate cancer	0.00804	0.0505	CbGeAlD
Vigabatrin—SLC36A1—testis—prostate cancer	0.00687	0.0431	CbGeAlD
Vigabatrin—ABAT—testis—prostate cancer	0.00683	0.0429	CbGeAlD
Vigabatrin—GABBR1—lymph node—prostate cancer	0.00634	0.0398	CbGeAlD
Vigabatrin—SLC36A1—lymph node—prostate cancer	0.00498	0.0313	CbGeAlD
Vigabatrin—ABAT—lymph node—prostate cancer	0.00495	0.0311	CbGeAlD
Vigabatrin—GABBR1—Potassium Channels—GNG5—prostate cancer	0.00177	0.0107	CbGpPWpGaD
Vigabatrin—ABAT—Transmission across Chemical Synapses—RRAS—prostate cancer	0.00173	0.0104	CbGpPWpGaD
Vigabatrin—SLC36A1—Transport of inorganic cations/anions and amino acids/oligopeptides—SLC5A5—prostate cancer	0.00154	0.00925	CbGpPWpGaD
Vigabatrin—GABBR1—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—PLCB2—prostate cancer	0.00148	0.00892	CbGpPWpGaD
Vigabatrin—GABBR1—Transmission across Chemical Synapses—RRAS—prostate cancer	0.00147	0.00885	CbGpPWpGaD
Vigabatrin—SLC36A1—SLC-mediated transmembrane transport—SLC12A2—prostate cancer	0.00142	0.00857	CbGpPWpGaD
Vigabatrin—SLC36A1—SLC-mediated transmembrane transport—SLC26A4—prostate cancer	0.00142	0.00857	CbGpPWpGaD
Vigabatrin—GABBR1—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—GNG5—prostate cancer	0.00134	0.00809	CbGpPWpGaD
Vigabatrin—ABAT—Neuronal System—RRAS—prostate cancer	0.00132	0.00797	CbGpPWpGaD
Vigabatrin—ABAT—Transmission across Chemical Synapses—PLCB2—prostate cancer	0.00131	0.00789	CbGpPWpGaD
Vigabatrin—ABAT—Transmission across Chemical Synapses—SLC22A1—prostate cancer	0.00125	0.00752	CbGpPWpGaD
Vigabatrin—GABBR1—G alpha (i) signalling events—PENK—prostate cancer	0.0012	0.00723	CbGpPWpGaD
Vigabatrin—ABAT—Transmission across Chemical Synapses—GNG5—prostate cancer	0.00119	0.00716	CbGpPWpGaD
Vigabatrin—SLC36A1—SLC-mediated transmembrane transport—SLC22A3—prostate cancer	0.00115	0.00695	CbGpPWpGaD
Vigabatrin—SLC36A1—Transmembrane transport of small molecules—SLC7A1—prostate cancer	0.00115	0.00694	CbGpPWpGaD
Vigabatrin—GABBR1—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—PRKACB—prostate cancer	0.00115	0.0069	CbGpPWpGaD
Vigabatrin—GABBR1—GPCR ligand binding—RLN2—prostate cancer	0.00113	0.00679	CbGpPWpGaD
Vigabatrin—GABBR1—Neuronal System—RRAS—prostate cancer	0.00113	0.00678	CbGpPWpGaD
Vigabatrin—GABBR1—Transmission across Chemical Synapses—PLCB2—prostate cancer	0.00111	0.0067	CbGpPWpGaD
Vigabatrin—GABBR1—Transmission across Chemical Synapses—SLC22A1—prostate cancer	0.00106	0.0064	CbGpPWpGaD
Vigabatrin—ABAT—Transmission across Chemical Synapses—ACHE—prostate cancer	0.00106	0.00638	CbGpPWpGaD
Vigabatrin—ABAT—Transmission across Chemical Synapses—PRKACB—prostate cancer	0.00101	0.0061	CbGpPWpGaD
Vigabatrin—GABBR1—Transmission across Chemical Synapses—GNG5—prostate cancer	0.00101	0.00608	CbGpPWpGaD
Vigabatrin—ABAT—Neuronal System—PLCB2—prostate cancer	0.001	0.00604	CbGpPWpGaD
Vigabatrin—GABBR1—GPCR ligand binding—GRPR—prostate cancer	0.000993	0.00598	CbGpPWpGaD
Vigabatrin—GABBR1—G alpha (i) signalling events—LPAR1—prostate cancer	0.000988	0.00595	CbGpPWpGaD
Vigabatrin—ABAT—Neuronal System—SLC22A1—prostate cancer	0.000957	0.00576	CbGpPWpGaD
Vigabatrin—SLC36A1—SLC-mediated transmembrane transport—SLC22A1—prostate cancer	0.000941	0.00567	CbGpPWpGaD
Vigabatrin—SLC36A1—Transmembrane transport of small molecules—SLC39A1—prostate cancer	0.00091	0.00548	CbGpPWpGaD
Vigabatrin—ABAT—Neuronal System—GNG5—prostate cancer	0.00091	0.00548	CbGpPWpGaD
Vigabatrin—GABBR1—Transmission across Chemical Synapses—ACHE—prostate cancer	0.0009	0.00542	CbGpPWpGaD
Vigabatrin—GABBR1—G alpha (i) signalling events—GNG5—prostate cancer	0.000888	0.00535	CbGpPWpGaD
Vigabatrin—GABBR1—Transmission across Chemical Synapses—PRKACB—prostate cancer	0.000861	0.00519	CbGpPWpGaD
Vigabatrin—GABBR1—GPCR ligand binding—WNT4—prostate cancer	0.000855	0.00515	CbGpPWpGaD
Vigabatrin—GABBR1—Neuronal System—PLCB2—prostate cancer	0.000853	0.00514	CbGpPWpGaD
Vigabatrin—GABBR1—GPCR downstream signaling—OR51E2—prostate cancer	0.000841	0.00507	CbGpPWpGaD
Vigabatrin—GABBR1—GPCR ligand binding—MC2R—prostate cancer	0.000815	0.00491	CbGpPWpGaD
Vigabatrin—GABBR1—Neuronal System—SLC22A1—prostate cancer	0.000814	0.0049	CbGpPWpGaD
Vigabatrin—ABAT—Neuronal System—ACHE—prostate cancer	0.000811	0.00489	CbGpPWpGaD
Vigabatrin—ABAT—Neuronal System—PRKACB—prostate cancer	0.000776	0.00467	CbGpPWpGaD
Vigabatrin—GABBR1—Neuronal System—GNG5—prostate cancer	0.000774	0.00466	CbGpPWpGaD
Vigabatrin—GABBR1—Signaling by GPCR—OR51E2—prostate cancer	0.000764	0.0046	CbGpPWpGaD
Vigabatrin—SLC36A1—Transmembrane transport of small molecules—CYP7B1—prostate cancer	0.000742	0.00447	CbGpPWpGaD
Vigabatrin—ABAT—Transmission across Chemical Synapses—COMT—prostate cancer	0.000737	0.00444	CbGpPWpGaD
Vigabatrin—GABBR1—G alpha (i) signalling events—ANXA1—prostate cancer	0.000727	0.00438	CbGpPWpGaD
Vigabatrin—GABBR1—GPCR ligand binding—PENK—prostate cancer	0.000727	0.00438	CbGpPWpGaD
Vigabatrin—SLC36A1—Transmembrane transport of small molecules—SLC26A4—prostate cancer	0.000723	0.00436	CbGpPWpGaD
Vigabatrin—SLC36A1—Transmembrane transport of small molecules—SLC12A2—prostate cancer	0.000723	0.00436	CbGpPWpGaD
Vigabatrin—GABBR1—GPCR downstream signaling—RGS17—prostate cancer	0.000715	0.00431	CbGpPWpGaD
Vigabatrin—GABBR1—Neuronal System—ACHE—prostate cancer	0.00069	0.00415	CbGpPWpGaD
Vigabatrin—SLC36A1—SLC-mediated transmembrane transport—SLC5A5—prostate cancer	0.000687	0.00414	CbGpPWpGaD
Vigabatrin—GABBR1—G alpha (i) signalling events—CXCL12—prostate cancer	0.000665	0.00401	CbGpPWpGaD
Vigabatrin—GABBR1—Neuronal System—PRKACB—prostate cancer	0.00066	0.00397	CbGpPWpGaD
Vigabatrin—GABBR1—Signaling by GPCR—RGS17—prostate cancer	0.000649	0.00391	CbGpPWpGaD
Vigabatrin—GABBR1—GPCR downstream signaling—RLN2—prostate cancer	0.000637	0.00384	CbGpPWpGaD
Vigabatrin—GABBR1—Transmission across Chemical Synapses—COMT—prostate cancer	0.000627	0.00378	CbGpPWpGaD
Vigabatrin—GABBR1—GPCR ligand binding—GNRH1—prostate cancer	0.000618	0.00372	CbGpPWpGaD
Vigabatrin—GABBR1—GPCR ligand binding—LPAR1—prostate cancer	0.000598	0.0036	CbGpPWpGaD
Vigabatrin—GABBR1—GPCR ligand binding—GRP—prostate cancer	0.000598	0.0036	CbGpPWpGaD
Vigabatrin—SLC36A1—Transmembrane transport of small molecules—SLC22A3—prostate cancer	0.000587	0.00353	CbGpPWpGaD
Vigabatrin—GABBR1—GPCR downstream signaling—PLXNB1—prostate cancer	0.000583	0.00351	CbGpPWpGaD
Vigabatrin—GABBR1—GPCR ligand binding—CX3CL1—prostate cancer	0.000581	0.0035	CbGpPWpGaD
Vigabatrin—GABBR1—Signaling by GPCR—RLN2—prostate cancer	0.000579	0.00349	CbGpPWpGaD
Vigabatrin—ABAT—Neuronal System—COMT—prostate cancer	0.000565	0.0034	CbGpPWpGaD
Vigabatrin—GABBR1—GPCR downstream signaling—GRPR—prostate cancer	0.000561	0.00338	CbGpPWpGaD
Vigabatrin—SLC36A1—Transmembrane transport of small molecules—ABCG5—prostate cancer	0.000541	0.00326	CbGpPWpGaD
Vigabatrin—GABBR1—GPCR ligand binding—GNG5—prostate cancer	0.000538	0.00324	CbGpPWpGaD
Vigabatrin—GABBR1—Signaling by GPCR—PLXNB1—prostate cancer	0.000529	0.00319	CbGpPWpGaD
Vigabatrin—GABBR1—Signaling by GPCR—GRPR—prostate cancer	0.000509	0.00307	CbGpPWpGaD
Vigabatrin—GABBR1—Neuronal System—COMT—prostate cancer	0.00048	0.00289	CbGpPWpGaD
Vigabatrin—SLC36A1—Transmembrane transport of small molecules—SLC22A1—prostate cancer	0.000478	0.00288	CbGpPWpGaD
Vigabatrin—GABBR1—GPCR ligand binding—PTHLH—prostate cancer	0.000468	0.00282	CbGpPWpGaD
Vigabatrin—GABBR1—GPCR downstream signaling—MC2R—prostate cancer	0.000461	0.00278	CbGpPWpGaD
Vigabatrin—SLC36A1—Transmembrane transport of small molecules—GNG5—prostate cancer	0.000455	0.00274	CbGpPWpGaD
Vigabatrin—GABBR1—Signaling Pathways—OR51E2—prostate cancer	0.000451	0.00272	CbGpPWpGaD
Vigabatrin—GABBR1—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—MDM2—prostate cancer	0.000446	0.00269	CbGpPWpGaD
Vigabatrin—GABBR1—GPCR ligand binding—ANXA1—prostate cancer	0.00044	0.00265	CbGpPWpGaD
Vigabatrin—GABBR1—Signaling by GPCR—WNT4—prostate cancer	0.000439	0.00264	CbGpPWpGaD
Vigabatrin—GABBR1—Signaling by GPCR—MC2R—prostate cancer	0.000418	0.00252	CbGpPWpGaD
Vigabatrin—GABBR1—Signaling Pathways—BMPR1B—prostate cancer	0.000413	0.00249	CbGpPWpGaD
Vigabatrin—GABBR1—GPCR ligand binding—CALCA—prostate cancer	0.000412	0.00248	CbGpPWpGaD
Vigabatrin—GABBR1—GPCR downstream signaling—PENK—prostate cancer	0.000411	0.00247	CbGpPWpGaD
Vigabatrin—GABBR1—GPCR ligand binding—CXCL12—prostate cancer	0.000403	0.00243	CbGpPWpGaD
Vigabatrin—ABAT—Transmission across Chemical Synapses—MDM2—prostate cancer	0.000394	0.00238	CbGpPWpGaD
Vigabatrin—SLC36A1—Transmembrane transport of small molecules—PRKACB—prostate cancer	0.000388	0.00234	CbGpPWpGaD
Vigabatrin—GABBR1—Signaling Pathways—RGS17—prostate cancer	0.000384	0.00231	CbGpPWpGaD
Vigabatrin—GABBR1—Signaling by GPCR—PENK—prostate cancer	0.000373	0.00225	CbGpPWpGaD
Vigabatrin—SLC36A1—Transmembrane transport of small molecules—NCOA2—prostate cancer	0.000366	0.0022	CbGpPWpGaD
Vigabatrin—GABBR1—GPCR downstream signaling—GNRH1—prostate cancer	0.000349	0.0021	CbGpPWpGaD
Vigabatrin—GABBR1—GPCR downstream signaling—VIP—prostate cancer	0.000349	0.0021	CbGpPWpGaD
Vigabatrin—SLC36A1—Transmembrane transport of small molecules—SLC5A5—prostate cancer	0.000349	0.0021	CbGpPWpGaD
Vigabatrin—GABBR1—GPCR ligand binding—ADRB2—prostate cancer	0.000345	0.00208	CbGpPWpGaD
Vigabatrin—GABBR1—Signaling Pathways—RLN2—prostate cancer	0.000342	0.00206	CbGpPWpGaD
Vigabatrin—GABBR1—GPCR downstream signaling—LPAR1—prostate cancer	0.000338	0.00204	CbGpPWpGaD
Vigabatrin—GABBR1—GPCR downstream signaling—GRP—prostate cancer	0.000338	0.00204	CbGpPWpGaD
Vigabatrin—GABBR1—Transmission across Chemical Synapses—MDM2—prostate cancer	0.000335	0.00202	CbGpPWpGaD
Vigabatrin—GABBR1—GPCR downstream signaling—PLCB2—prostate cancer	0.000335	0.00202	CbGpPWpGaD
Vigabatrin—GABBR1—Signaling Pathways—HSD17B1—prostate cancer	0.000326	0.00196	CbGpPWpGaD
Vigabatrin—GABBR1—Signaling Pathways—CTBP2—prostate cancer	0.000326	0.00196	CbGpPWpGaD
Vigabatrin—GABBR1—GPCR downstream signaling—PDE4D—prostate cancer	0.000319	0.00192	CbGpPWpGaD
Vigabatrin—GABBR1—Signaling by GPCR—VIP—prostate cancer	0.000317	0.00191	CbGpPWpGaD
Vigabatrin—GABBR1—Signaling by GPCR—GNRH1—prostate cancer	0.000317	0.00191	CbGpPWpGaD
Vigabatrin—GABBR1—Signaling Pathways—PLXNB1—prostate cancer	0.000313	0.00188	CbGpPWpGaD
Vigabatrin—SLC36A1—Transmembrane transport of small molecules—NCOA1—prostate cancer	0.000308	0.00186	CbGpPWpGaD
Vigabatrin—GABBR1—Signaling by GPCR—GRP—prostate cancer	0.000307	0.00185	CbGpPWpGaD
Vigabatrin—GABBR1—Signaling by GPCR—LPAR1—prostate cancer	0.000307	0.00185	CbGpPWpGaD
Vigabatrin—GABBR1—Signaling by GPCR—PLCB2—prostate cancer	0.000304	0.00183	CbGpPWpGaD
Vigabatrin—GABBR1—GPCR downstream signaling—GNG5—prostate cancer	0.000304	0.00183	CbGpPWpGaD
Vigabatrin—ABAT—Neuronal System—MDM2—prostate cancer	0.000302	0.00182	CbGpPWpGaD
Vigabatrin—GABBR1—Signaling Pathways—GRPR—prostate cancer	0.000301	0.00181	CbGpPWpGaD
Vigabatrin—GABBR1—Signaling by GPCR—CX3CL1—prostate cancer	0.000298	0.0018	CbGpPWpGaD
Vigabatrin—SLC36A1—Transmembrane transport of small molecules—RXRA—prostate cancer	0.000293	0.00177	CbGpPWpGaD
Vigabatrin—GABBR1—Signaling Pathways—IL17RD—prostate cancer	0.000291	0.00175	CbGpPWpGaD
Vigabatrin—GABBR1—Signaling by GPCR—PDE4D—prostate cancer	0.00029	0.00175	CbGpPWpGaD
Vigabatrin—GABBR1—Signaling by GPCR—GNG5—prostate cancer	0.000276	0.00166	CbGpPWpGaD
Vigabatrin—GABBR1—G alpha (i) signalling events—CXCL8—prostate cancer	0.000276	0.00166	CbGpPWpGaD
Vigabatrin—GABBR1—GPCR downstream signaling—PTHLH—prostate cancer	0.000265	0.00159	CbGpPWpGaD
Vigabatrin—GABBR1—Signaling Pathways—JUP—prostate cancer	0.000259	0.00156	CbGpPWpGaD
Vigabatrin—GABBR1—Signaling Pathways—WNT4—prostate cancer	0.000259	0.00156	CbGpPWpGaD
Vigabatrin—GABBR1—Neuronal System—MDM2—prostate cancer	0.000257	0.00155	CbGpPWpGaD
Vigabatrin—GABBR1—GPCR downstream signaling—ANXA1—prostate cancer	0.000249	0.0015	CbGpPWpGaD
Vigabatrin—GABBR1—Signaling Pathways—RALBP1—prostate cancer	0.000247	0.00149	CbGpPWpGaD
Vigabatrin—GABBR1—Signaling Pathways—MC2R—prostate cancer	0.000247	0.00149	CbGpPWpGaD
Vigabatrin—GABBR1—Signaling by GPCR—PTHLH—prostate cancer	0.00024	0.00145	CbGpPWpGaD
Vigabatrin—GABBR1—Signaling by GPCR—PRKACB—prostate cancer	0.000235	0.00142	CbGpPWpGaD
Vigabatrin—GABBR1—GPCR downstream signaling—CALCA—prostate cancer	0.000233	0.0014	CbGpPWpGaD
Vigabatrin—GABBR1—Signaling by GPCR—PPP3CA—prostate cancer	0.000229	0.00138	CbGpPWpGaD
Vigabatrin—GABBR1—GPCR downstream signaling—CXCL12—prostate cancer	0.000228	0.00137	CbGpPWpGaD
Vigabatrin—GABBR1—Signaling by GPCR—ANXA1—prostate cancer	0.000226	0.00136	CbGpPWpGaD
Vigabatrin—SLC36A1—Transmembrane transport of small molecules—PPARA—prostate cancer	0.000224	0.00135	CbGpPWpGaD
Vigabatrin—GABBR1—Signaling Pathways—PENK—prostate cancer	0.00022	0.00133	CbGpPWpGaD
Vigabatrin—GABBR1—Signaling by GPCR—CALCA—prostate cancer	0.000212	0.00127	CbGpPWpGaD
Vigabatrin—GABBR1—Signaling Pathways—GHR—prostate cancer	0.00021	0.00127	CbGpPWpGaD
Vigabatrin—GABBR1—GPCR downstream signaling—PRKCQ—prostate cancer	0.000208	0.00125	CbGpPWpGaD
Vigabatrin—GABBR1—Signaling by GPCR—CXCL12—prostate cancer	0.000207	0.00124	CbGpPWpGaD
Vigabatrin—GABBR1—Signaling Pathways—NRP1—prostate cancer	0.000201	0.00121	CbGpPWpGaD
Vigabatrin—GABBR1—GPCR downstream signaling—ADRB2—prostate cancer	0.000195	0.00118	CbGpPWpGaD
Vigabatrin—GABBR1—GPCR downstream signaling—VAV3—prostate cancer	0.00019	0.00115	CbGpPWpGaD
Vigabatrin—GABBR1—Signaling by GPCR—PRKCQ—prostate cancer	0.000189	0.00114	CbGpPWpGaD
Vigabatrin—GABBR1—Signaling Pathways—VIP—prostate cancer	0.000187	0.00113	CbGpPWpGaD
Vigabatrin—GABBR1—Signaling Pathways—GNRH1—prostate cancer	0.000187	0.00113	CbGpPWpGaD
Vigabatrin—Hepatobiliary disease—Epirubicin—prostate cancer	0.000185	0.000279	CcSEcCtD
Vigabatrin—Oedema—Docetaxel—prostate cancer	0.000185	0.000278	CcSEcCtD
Vigabatrin—Weight increased—Doxorubicin—prostate cancer	0.000185	0.000278	CcSEcCtD
Vigabatrin—Discomfort—Capecitabine—prostate cancer	0.000185	0.000278	CcSEcCtD
Vigabatrin—GABBR1—GPCR downstream signaling—ITPR1—prostate cancer	0.000185	0.00111	CbGpPWpGaD
Vigabatrin—Vision blurred—Prednisone—prostate cancer	0.000184	0.000277	CcSEcCtD
Vigabatrin—Infection—Docetaxel—prostate cancer	0.000184	0.000277	CcSEcCtD
Vigabatrin—Sinusitis—Epirubicin—prostate cancer	0.000184	0.000276	CcSEcCtD
Vigabatrin—Feeling abnormal—Etoposide—prostate cancer	0.000184	0.000276	CcSEcCtD
Vigabatrin—Diarrhoea—Mitoxantrone—prostate cancer	0.000183	0.000276	CcSEcCtD
Vigabatrin—Vomiting—Estradiol—prostate cancer	0.000183	0.000275	CcSEcCtD
Vigabatrin—Pneumonia—Doxorubicin—prostate cancer	0.000182	0.000274	CcSEcCtD
Vigabatrin—Gastrointestinal pain—Etoposide—prostate cancer	0.000182	0.000274	CcSEcCtD
Vigabatrin—Nervous system disorder—Docetaxel—prostate cancer	0.000182	0.000273	CcSEcCtD
Vigabatrin—Ill-defined disorder—Prednisone—prostate cancer	0.000182	0.000273	CcSEcCtD
Vigabatrin—GABBR1—Signaling Pathways—LPAR1—prostate cancer	0.000181	0.00109	CbGpPWpGaD
Vigabatrin—GABBR1—Signaling Pathways—GRP—prostate cancer	0.000181	0.00109	CbGpPWpGaD
Vigabatrin—Rash—Estradiol—prostate cancer	0.000181	0.000273	CcSEcCtD
Vigabatrin—Infestation—Doxorubicin—prostate cancer	0.000181	0.000273	CcSEcCtD
Vigabatrin—Infestation NOS—Doxorubicin—prostate cancer	0.000181	0.000273	CcSEcCtD
Vigabatrin—Drowsiness—Doxorubicin—prostate cancer	0.000181	0.000273	CcSEcCtD
Vigabatrin—Dermatitis—Estradiol—prostate cancer	0.000181	0.000272	CcSEcCtD
Vigabatrin—Anaemia—Prednisone—prostate cancer	0.000181	0.000272	CcSEcCtD
Vigabatrin—Confusional state—Capecitabine—prostate cancer	0.000181	0.000272	CcSEcCtD
Vigabatrin—Headache—Estradiol—prostate cancer	0.00018	0.000271	CcSEcCtD
Vigabatrin—Skin disorder—Docetaxel—prostate cancer	0.00018	0.000271	CcSEcCtD
Vigabatrin—Agitation—Prednisone—prostate cancer	0.00018	0.00027	CcSEcCtD
Vigabatrin—Stevens-Johnson syndrome—Doxorubicin—prostate cancer	0.00018	0.00027	CcSEcCtD
Vigabatrin—GABBR1—Signaling Pathways—PLCB2—prostate cancer	0.00018	0.00108	CbGpPWpGaD
Vigabatrin—GABBR1—Signaling Pathways—LRP2—prostate cancer	0.00018	0.00108	CbGpPWpGaD
Vigabatrin—Oedema—Capecitabine—prostate cancer	0.000179	0.00027	CcSEcCtD
Vigabatrin—Angioedema—Prednisone—prostate cancer	0.000179	0.000269	CcSEcCtD
Vigabatrin—Infection—Capecitabine—prostate cancer	0.000178	0.000268	CcSEcCtD
Vigabatrin—SLC36A1—Transmembrane transport of small molecules—CREBBP—prostate cancer	0.000178	0.00107	CbGpPWpGaD
Vigabatrin—Neuropathy peripheral—Doxorubicin—prostate cancer	0.000178	0.000267	CcSEcCtD
Vigabatrin—GABBR1—Signaling by GPCR—ADRB2—prostate cancer	0.000177	0.00107	CbGpPWpGaD
Vigabatrin—Urticaria—Etoposide—prostate cancer	0.000177	0.000266	CcSEcCtD
Vigabatrin—Malaise—Prednisone—prostate cancer	0.000176	0.000265	CcSEcCtD
Vigabatrin—GABBR1—Signaling Pathways—P4HB—prostate cancer	0.000176	0.00106	CbGpPWpGaD
Vigabatrin—GABBR1—Signaling Pathways—CX3CL1—prostate cancer	0.000176	0.00106	CbGpPWpGaD
Vigabatrin—Body temperature increased—Etoposide—prostate cancer	0.000176	0.000265	CcSEcCtD
Vigabatrin—Abdominal pain—Etoposide—prostate cancer	0.000176	0.000265	CcSEcCtD
Vigabatrin—Urinary tract infection—Doxorubicin—prostate cancer	0.000176	0.000265	CcSEcCtD
Vigabatrin—Conjunctivitis—Doxorubicin—prostate cancer	0.000176	0.000265	CcSEcCtD
Vigabatrin—Nervous system disorder—Capecitabine—prostate cancer	0.000176	0.000264	CcSEcCtD
Vigabatrin—Vertigo—Prednisone—prostate cancer	0.000176	0.000264	CcSEcCtD
Vigabatrin—Hypoaesthesia—Epirubicin—prostate cancer	0.000175	0.000263	CcSEcCtD
Vigabatrin—Skin disorder—Capecitabine—prostate cancer	0.000174	0.000262	CcSEcCtD
Vigabatrin—Oedema peripheral—Epirubicin—prostate cancer	0.000173	0.00026	CcSEcCtD
Vigabatrin—GABBR1—Signaling by GPCR—VAV3—prostate cancer	0.000173	0.00104	CbGpPWpGaD
Vigabatrin—GABBR1—Signaling Pathways—HIST1H2BG—prostate cancer	0.000173	0.00104	CbGpPWpGaD
Vigabatrin—Connective tissue disorder—Epirubicin—prostate cancer	0.000173	0.00026	CcSEcCtD
Vigabatrin—Hepatobiliary disease—Doxorubicin—prostate cancer	0.000171	0.000258	CcSEcCtD
Vigabatrin—GABBR1—Signaling Pathways—GRB7—prostate cancer	0.000171	0.00103	CbGpPWpGaD
Vigabatrin—GABBR1—Signaling Pathways—PDE4D—prostate cancer	0.000171	0.00103	CbGpPWpGaD
Vigabatrin—Nausea—Estradiol—prostate cancer	0.000171	0.000257	CcSEcCtD
Vigabatrin—Vomiting—Mitoxantrone—prostate cancer	0.00017	0.000256	CcSEcCtD
Vigabatrin—Sinusitis—Doxorubicin—prostate cancer	0.00017	0.000256	CcSEcCtD
Vigabatrin—Convulsion—Prednisone—prostate cancer	0.000169	0.000255	CcSEcCtD
Vigabatrin—Visual impairment—Epirubicin—prostate cancer	0.000169	0.000255	CcSEcCtD
Vigabatrin—Rash—Mitoxantrone—prostate cancer	0.000169	0.000254	CcSEcCtD
Vigabatrin—Dermatitis—Mitoxantrone—prostate cancer	0.000169	0.000254	CcSEcCtD
Vigabatrin—Musculoskeletal discomfort—Docetaxel—prostate cancer	0.000169	0.000254	CcSEcCtD
Vigabatrin—Headache—Mitoxantrone—prostate cancer	0.000168	0.000252	CcSEcCtD
Vigabatrin—GABBR1—Signaling by GPCR—ITPR1—prostate cancer	0.000168	0.00101	CbGpPWpGaD
Vigabatrin—Insomnia—Docetaxel—prostate cancer	0.000167	0.000252	CcSEcCtD
Vigabatrin—GABBR1—Signaling Pathways—HIST1H4H—prostate cancer	0.000167	0.00101	CbGpPWpGaD
Vigabatrin—GABBR1—GPCR ligand binding—CXCL8—prostate cancer	0.000167	0.00101	CbGpPWpGaD
Vigabatrin—Arthralgia—Prednisone—prostate cancer	0.000167	0.000251	CcSEcCtD
Vigabatrin—Myalgia—Prednisone—prostate cancer	0.000167	0.000251	CcSEcCtD
Vigabatrin—Paraesthesia—Docetaxel—prostate cancer	0.000166	0.00025	CcSEcCtD
Vigabatrin—Erythema multiforme—Epirubicin—prostate cancer	0.000166	0.00025	CcSEcCtD
Vigabatrin—Anxiety—Prednisone—prostate cancer	0.000166	0.00025	CcSEcCtD
Vigabatrin—Unspecified disorder of skin and subcutaneous tissue—Prednisone—prostate cancer	0.000165	0.000249	CcSEcCtD
Vigabatrin—Somnolence—Docetaxel—prostate cancer	0.000165	0.000248	CcSEcCtD
Vigabatrin—Discomfort—Prednisone—prostate cancer	0.000165	0.000248	CcSEcCtD
Vigabatrin—Eye disorder—Epirubicin—prostate cancer	0.000164	0.000247	CcSEcCtD
Vigabatrin—Hypersensitivity—Etoposide—prostate cancer	0.000164	0.000247	CcSEcCtD
Vigabatrin—Tinnitus—Epirubicin—prostate cancer	0.000164	0.000247	CcSEcCtD
Vigabatrin—Musculoskeletal discomfort—Capecitabine—prostate cancer	0.000163	0.000246	CcSEcCtD
Vigabatrin—Dyspepsia—Docetaxel—prostate cancer	0.000163	0.000245	CcSEcCtD
Vigabatrin—GABBR1—Signaling Pathways—GNG5—prostate cancer	0.000163	0.000982	CbGpPWpGaD
Vigabatrin—Insomnia—Capecitabine—prostate cancer	0.000162	0.000244	CcSEcCtD
Vigabatrin—Hypoaesthesia—Doxorubicin—prostate cancer	0.000162	0.000243	CcSEcCtD
Vigabatrin—Paraesthesia—Capecitabine—prostate cancer	0.000161	0.000242	CcSEcCtD
Vigabatrin—Decreased appetite—Docetaxel—prostate cancer	0.000161	0.000242	CcSEcCtD
Vigabatrin—Oedema peripheral—Doxorubicin—prostate cancer	0.00016	0.000241	CcSEcCtD
Vigabatrin—Gastrointestinal disorder—Docetaxel—prostate cancer	0.00016	0.00024	CcSEcCtD
Vigabatrin—Asthenia—Etoposide—prostate cancer	0.00016	0.00024	CcSEcCtD
Vigabatrin—Connective tissue disorder—Doxorubicin—prostate cancer	0.00016	0.00024	CcSEcCtD
Vigabatrin—Oedema—Prednisone—prostate cancer	0.00016	0.00024	CcSEcCtD
Vigabatrin—Fatigue—Docetaxel—prostate cancer	0.00016	0.00024	CcSEcCtD
Vigabatrin—Nausea—Mitoxantrone—prostate cancer	0.000159	0.000239	CcSEcCtD
Vigabatrin—Infection—Prednisone—prostate cancer	0.000159	0.000239	CcSEcCtD
Vigabatrin—Pain—Docetaxel—prostate cancer	0.000158	0.000238	CcSEcCtD
Vigabatrin—Constipation—Docetaxel—prostate cancer	0.000158	0.000238	CcSEcCtD
Vigabatrin—Dyspepsia—Capecitabine—prostate cancer	0.000158	0.000237	CcSEcCtD
Vigabatrin—Pruritus—Etoposide—prostate cancer	0.000158	0.000237	CcSEcCtD
Vigabatrin—Visual impairment—Doxorubicin—prostate cancer	0.000157	0.000236	CcSEcCtD
Vigabatrin—Nervous system disorder—Prednisone—prostate cancer	0.000157	0.000236	CcSEcCtD
Vigabatrin—Decreased appetite—Capecitabine—prostate cancer	0.000156	0.000234	CcSEcCtD
Vigabatrin—Skin disorder—Prednisone—prostate cancer	0.000155	0.000233	CcSEcCtD
Vigabatrin—Gastrointestinal disorder—Capecitabine—prostate cancer	0.000155	0.000233	CcSEcCtD
Vigabatrin—Fatigue—Capecitabine—prostate cancer	0.000155	0.000232	CcSEcCtD
Vigabatrin—Mental disorder—Epirubicin—prostate cancer	0.000154	0.000232	CcSEcCtD
Vigabatrin—Erythema multiforme—Doxorubicin—prostate cancer	0.000154	0.000231	CcSEcCtD
Vigabatrin—Pain—Capecitabine—prostate cancer	0.000153	0.000231	CcSEcCtD
Vigabatrin—Constipation—Capecitabine—prostate cancer	0.000153	0.000231	CcSEcCtD
Vigabatrin—Malnutrition—Epirubicin—prostate cancer	0.000153	0.00023	CcSEcCtD
Vigabatrin—Feeling abnormal—Docetaxel—prostate cancer	0.000153	0.000229	CcSEcCtD
Vigabatrin—Diarrhoea—Etoposide—prostate cancer	0.000152	0.000229	CcSEcCtD
Vigabatrin—Eye disorder—Doxorubicin—prostate cancer	0.000152	0.000229	CcSEcCtD
Vigabatrin—Tinnitus—Doxorubicin—prostate cancer	0.000152	0.000228	CcSEcCtD
Vigabatrin—Gastrointestinal pain—Docetaxel—prostate cancer	0.000151	0.000228	CcSEcCtD
Vigabatrin—Tension—Epirubicin—prostate cancer	0.00015	0.000226	CcSEcCtD
Vigabatrin—Nervousness—Epirubicin—prostate cancer	0.000149	0.000224	CcSEcCtD
Vigabatrin—Back pain—Epirubicin—prostate cancer	0.000148	0.000223	CcSEcCtD
Vigabatrin—Feeling abnormal—Capecitabine—prostate cancer	0.000148	0.000222	CcSEcCtD
Vigabatrin—Dizziness—Etoposide—prostate cancer	0.000147	0.000222	CcSEcCtD
Vigabatrin—Muscle spasms—Epirubicin—prostate cancer	0.000147	0.000221	CcSEcCtD
Vigabatrin—Gastrointestinal pain—Capecitabine—prostate cancer	0.000147	0.00022	CcSEcCtD
Vigabatrin—Abdominal pain—Docetaxel—prostate cancer	0.000146	0.00022	CcSEcCtD
Vigabatrin—Body temperature increased—Docetaxel—prostate cancer	0.000146	0.00022	CcSEcCtD
Vigabatrin—Musculoskeletal discomfort—Prednisone—prostate cancer	0.000145	0.000219	CcSEcCtD
Vigabatrin—Insomnia—Prednisone—prostate cancer	0.000144	0.000217	CcSEcCtD
Vigabatrin—Vision blurred—Epirubicin—prostate cancer	0.000144	0.000217	CcSEcCtD
Vigabatrin—Paraesthesia—Prednisone—prostate cancer	0.000143	0.000216	CcSEcCtD
Vigabatrin—Mental disorder—Doxorubicin—prostate cancer	0.000142	0.000214	CcSEcCtD
Vigabatrin—Urticaria—Capecitabine—prostate cancer	0.000142	0.000214	CcSEcCtD
Vigabatrin—Ill-defined disorder—Epirubicin—prostate cancer	0.000142	0.000214	CcSEcCtD
Vigabatrin—GABBR1—Signaling Pathways—TGFBR1—prostate cancer	0.000142	0.000855	CbGpPWpGaD
Vigabatrin—GABBR1—Signaling Pathways—PTHLH—prostate cancer	0.000142	0.000855	CbGpPWpGaD
Vigabatrin—Abdominal pain—Capecitabine—prostate cancer	0.000142	0.000213	CcSEcCtD
Vigabatrin—Body temperature increased—Capecitabine—prostate cancer	0.000142	0.000213	CcSEcCtD
Vigabatrin—Vomiting—Etoposide—prostate cancer	0.000142	0.000213	CcSEcCtD
Vigabatrin—Malnutrition—Doxorubicin—prostate cancer	0.000142	0.000213	CcSEcCtD
Vigabatrin—Anaemia—Epirubicin—prostate cancer	0.000141	0.000213	CcSEcCtD
Vigabatrin—Agitation—Epirubicin—prostate cancer	0.000141	0.000212	CcSEcCtD
Vigabatrin—Dyspepsia—Prednisone—prostate cancer	0.000141	0.000211	CcSEcCtD
Vigabatrin—Rash—Etoposide—prostate cancer	0.00014	0.000211	CcSEcCtD
Vigabatrin—Dermatitis—Etoposide—prostate cancer	0.00014	0.000211	CcSEcCtD
Vigabatrin—GABBR1—Signaling Pathways—AKR1C3—prostate cancer	0.00014	0.000841	CbGpPWpGaD
Vigabatrin—Headache—Etoposide—prostate cancer	0.00014	0.00021	CcSEcCtD
Vigabatrin—Tension—Doxorubicin—prostate cancer	0.000139	0.000209	CcSEcCtD
Vigabatrin—GABBR1—Signaling Pathways—PRKACB—prostate cancer	0.000139	0.000837	CbGpPWpGaD
Vigabatrin—Decreased appetite—Prednisone—prostate cancer	0.000139	0.000209	CcSEcCtD
Vigabatrin—Malaise—Epirubicin—prostate cancer	0.000138	0.000208	CcSEcCtD
Vigabatrin—Fatigue—Prednisone—prostate cancer	0.000138	0.000207	CcSEcCtD
Vigabatrin—Nervousness—Doxorubicin—prostate cancer	0.000137	0.000207	CcSEcCtD
Vigabatrin—Vertigo—Epirubicin—prostate cancer	0.000137	0.000207	CcSEcCtD
Vigabatrin—Back pain—Doxorubicin—prostate cancer	0.000137	0.000206	CcSEcCtD
Vigabatrin—Constipation—Prednisone—prostate cancer	0.000137	0.000205	CcSEcCtD
Vigabatrin—Hypersensitivity—Docetaxel—prostate cancer	0.000136	0.000205	CcSEcCtD
Vigabatrin—Muscle spasms—Doxorubicin—prostate cancer	0.000136	0.000205	CcSEcCtD
Vigabatrin—GABBR1—Signaling Pathways—THBS1—prostate cancer	0.000135	0.000816	CbGpPWpGaD
Vigabatrin—GABBR1—Signaling Pathways—PPP3CA—prostate cancer	0.000135	0.000816	CbGpPWpGaD
Vigabatrin—Cough—Epirubicin—prostate cancer	0.000134	0.000201	CcSEcCtD
Vigabatrin—GABBR1—Signaling Pathways—ANXA1—prostate cancer	0.000133	0.000804	CbGpPWpGaD
Vigabatrin—Vision blurred—Doxorubicin—prostate cancer	0.000133	0.000201	CcSEcCtD
Vigabatrin—Asthenia—Docetaxel—prostate cancer	0.000133	0.0002	CcSEcCtD
Vigabatrin—Convulsion—Epirubicin—prostate cancer	0.000133	0.000199	CcSEcCtD
Vigabatrin—Nausea—Etoposide—prostate cancer	0.000132	0.000199	CcSEcCtD
Vigabatrin—Hypersensitivity—Capecitabine—prostate cancer	0.000132	0.000199	CcSEcCtD
Vigabatrin—Feeling abnormal—Prednisone—prostate cancer	0.000132	0.000198	CcSEcCtD
Vigabatrin—Ill-defined disorder—Doxorubicin—prostate cancer	0.000131	0.000198	CcSEcCtD
Vigabatrin—GABBR1—Signaling Pathways—PRKCZ—prostate cancer	0.000131	0.000789	CbGpPWpGaD
Vigabatrin—Pruritus—Docetaxel—prostate cancer	0.000131	0.000197	CcSEcCtD
Vigabatrin—Anaemia—Doxorubicin—prostate cancer	0.000131	0.000197	CcSEcCtD
Vigabatrin—Gastrointestinal pain—Prednisone—prostate cancer	0.000131	0.000196	CcSEcCtD
Vigabatrin—Chest pain—Epirubicin—prostate cancer	0.00013	0.000196	CcSEcCtD
Vigabatrin—Myalgia—Epirubicin—prostate cancer	0.00013	0.000196	CcSEcCtD
Vigabatrin—Arthralgia—Epirubicin—prostate cancer	0.00013	0.000196	CcSEcCtD
Vigabatrin—Agitation—Doxorubicin—prostate cancer	0.00013	0.000196	CcSEcCtD
Vigabatrin—Anxiety—Epirubicin—prostate cancer	0.00013	0.000195	CcSEcCtD
Vigabatrin—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—prostate cancer	0.000129	0.000195	CcSEcCtD
Vigabatrin—Discomfort—Epirubicin—prostate cancer	0.000129	0.000194	CcSEcCtD
Vigabatrin—Asthenia—Capecitabine—prostate cancer	0.000129	0.000193	CcSEcCtD
Vigabatrin—GABBR1—GPCR downstream signaling—PIK3CG—prostate cancer	0.000128	0.000771	CbGpPWpGaD
Vigabatrin—Malaise—Doxorubicin—prostate cancer	0.000128	0.000192	CcSEcCtD
Vigabatrin—Vertigo—Doxorubicin—prostate cancer	0.000127	0.000191	CcSEcCtD
Vigabatrin—Urticaria—Prednisone—prostate cancer	0.000127	0.000191	CcSEcCtD
Vigabatrin—Pruritus—Capecitabine—prostate cancer	0.000127	0.000191	CcSEcCtD
Vigabatrin—Diarrhoea—Docetaxel—prostate cancer	0.000127	0.000191	CcSEcCtD
Vigabatrin—GABBR1—Signaling Pathways—FGFR4—prostate cancer	0.000127	0.000762	CbGpPWpGaD
Vigabatrin—GABBR1—Signaling Pathways—PARP1—prostate cancer	0.000127	0.000762	CbGpPWpGaD
Vigabatrin—Abdominal pain—Prednisone—prostate cancer	0.000126	0.00019	CcSEcCtD
Vigabatrin—Body temperature increased—Prednisone—prostate cancer	0.000126	0.00019	CcSEcCtD
Vigabatrin—Confusional state—Epirubicin—prostate cancer	0.000126	0.000189	CcSEcCtD
Vigabatrin—GABBR1—Signaling Pathways—CALCA—prostate cancer	0.000125	0.000753	CbGpPWpGaD
Vigabatrin—Oedema—Epirubicin—prostate cancer	0.000125	0.000188	CcSEcCtD
Vigabatrin—Infection—Epirubicin—prostate cancer	0.000124	0.000187	CcSEcCtD
Vigabatrin—Cough—Doxorubicin—prostate cancer	0.000124	0.000186	CcSEcCtD
Vigabatrin—Convulsion—Doxorubicin—prostate cancer	0.000123	0.000185	CcSEcCtD
Vigabatrin—Diarrhoea—Capecitabine—prostate cancer	0.000123	0.000184	CcSEcCtD
Vigabatrin—Nervous system disorder—Epirubicin—prostate cancer	0.000122	0.000184	CcSEcCtD
Vigabatrin—Dizziness—Docetaxel—prostate cancer	0.000122	0.000184	CcSEcCtD
Vigabatrin—GABBR1—Signaling Pathways—CXCL12—prostate cancer	0.000122	0.000735	CbGpPWpGaD
Vigabatrin—Skin disorder—Epirubicin—prostate cancer	0.000121	0.000182	CcSEcCtD
Vigabatrin—Myalgia—Doxorubicin—prostate cancer	0.000121	0.000181	CcSEcCtD
Vigabatrin—Arthralgia—Doxorubicin—prostate cancer	0.000121	0.000181	CcSEcCtD
Vigabatrin—Chest pain—Doxorubicin—prostate cancer	0.000121	0.000181	CcSEcCtD
Vigabatrin—Anxiety—Doxorubicin—prostate cancer	0.00012	0.000181	CcSEcCtD
Vigabatrin—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—prostate cancer	0.00012	0.00018	CcSEcCtD
Vigabatrin—Discomfort—Doxorubicin—prostate cancer	0.000119	0.000179	CcSEcCtD
Vigabatrin—Dizziness—Capecitabine—prostate cancer	0.000119	0.000178	CcSEcCtD
Vigabatrin—Vomiting—Docetaxel—prostate cancer	0.000118	0.000177	CcSEcCtD
Vigabatrin—Hypersensitivity—Prednisone—prostate cancer	0.000118	0.000177	CcSEcCtD
Vigabatrin—Rash—Docetaxel—prostate cancer	0.000117	0.000176	CcSEcCtD
Vigabatrin—Dermatitis—Docetaxel—prostate cancer	0.000117	0.000175	CcSEcCtD
Vigabatrin—Confusional state—Doxorubicin—prostate cancer	0.000116	0.000175	CcSEcCtD
Vigabatrin—GABBR1—Signaling by GPCR—PIK3CG—prostate cancer	0.000116	0.0007	CbGpPWpGaD
Vigabatrin—Headache—Docetaxel—prostate cancer	0.000116	0.000174	CcSEcCtD
Vigabatrin—Oedema—Doxorubicin—prostate cancer	0.000116	0.000174	CcSEcCtD
Vigabatrin—GABBR1—Signaling Pathways—CASP9—prostate cancer	0.000115	0.000692	CbGpPWpGaD
Vigabatrin—Infection—Doxorubicin—prostate cancer	0.000115	0.000173	CcSEcCtD
Vigabatrin—Asthenia—Prednisone—prostate cancer	0.000115	0.000172	CcSEcCtD
Vigabatrin—Vomiting—Capecitabine—prostate cancer	0.000114	0.000171	CcSEcCtD
Vigabatrin—Musculoskeletal discomfort—Epirubicin—prostate cancer	0.000114	0.000171	CcSEcCtD
Vigabatrin—Nervous system disorder—Doxorubicin—prostate cancer	0.000113	0.00017	CcSEcCtD
Vigabatrin—Rash—Capecitabine—prostate cancer	0.000113	0.00017	CcSEcCtD
Vigabatrin—Pruritus—Prednisone—prostate cancer	0.000113	0.00017	CcSEcCtD
Vigabatrin—Insomnia—Epirubicin—prostate cancer	0.000113	0.00017	CcSEcCtD
Vigabatrin—Dermatitis—Capecitabine—prostate cancer	0.000113	0.00017	CcSEcCtD
Vigabatrin—GABBR1—GPCR downstream signaling—PIK3CD—prostate cancer	0.000113	0.000678	CbGpPWpGaD
Vigabatrin—Headache—Capecitabine—prostate cancer	0.000112	0.000169	CcSEcCtD
Vigabatrin—Skin disorder—Doxorubicin—prostate cancer	0.000112	0.000169	CcSEcCtD
Vigabatrin—Paraesthesia—Epirubicin—prostate cancer	0.000112	0.000169	CcSEcCtD
Vigabatrin—GABBR1—Signaling Pathways—NGFR—prostate cancer	0.000111	0.000671	CbGpPWpGaD
Vigabatrin—GABBR1—Signaling Pathways—PRKCQ—prostate cancer	0.000111	0.000671	CbGpPWpGaD
Vigabatrin—Somnolence—Epirubicin—prostate cancer	0.000111	0.000167	CcSEcCtD
Vigabatrin—GABBR1—Signaling Pathways—MAP3K7—prostate cancer	0.00011	0.000663	CbGpPWpGaD
Vigabatrin—Nausea—Docetaxel—prostate cancer	0.00011	0.000165	CcSEcCtD
Vigabatrin—Dyspepsia—Epirubicin—prostate cancer	0.00011	0.000165	CcSEcCtD
Vigabatrin—Diarrhoea—Prednisone—prostate cancer	0.000109	0.000164	CcSEcCtD
Vigabatrin—Decreased appetite—Epirubicin—prostate cancer	0.000109	0.000163	CcSEcCtD
Vigabatrin—Gastrointestinal disorder—Epirubicin—prostate cancer	0.000108	0.000162	CcSEcCtD
Vigabatrin—Fatigue—Epirubicin—prostate cancer	0.000108	0.000162	CcSEcCtD
Vigabatrin—Pain—Epirubicin—prostate cancer	0.000107	0.000161	CcSEcCtD
Vigabatrin—Constipation—Epirubicin—prostate cancer	0.000107	0.000161	CcSEcCtD
Vigabatrin—Nausea—Capecitabine—prostate cancer	0.000106	0.00016	CcSEcCtD
Vigabatrin—GABBR1—Signaling Pathways—FGF10—prostate cancer	0.000106	0.000638	CbGpPWpGaD
Vigabatrin—Dizziness—Prednisone—prostate cancer	0.000106	0.000159	CcSEcCtD
Vigabatrin—Musculoskeletal discomfort—Doxorubicin—prostate cancer	0.000105	0.000158	CcSEcCtD
Vigabatrin—GABBR1—Signaling Pathways—ADRB2—prostate cancer	0.000105	0.000631	CbGpPWpGaD
Vigabatrin—Insomnia—Doxorubicin—prostate cancer	0.000104	0.000157	CcSEcCtD
Vigabatrin—Paraesthesia—Doxorubicin—prostate cancer	0.000104	0.000156	CcSEcCtD
Vigabatrin—GABBR1—GPCR downstream signaling—JAK2—prostate cancer	0.000103	0.000622	CbGpPWpGaD
Vigabatrin—GABBR1—Signaling by GPCR—MAP2K1—prostate cancer	0.000103	0.00062	CbGpPWpGaD
Vigabatrin—Feeling abnormal—Epirubicin—prostate cancer	0.000103	0.000155	CcSEcCtD
Vigabatrin—Somnolence—Doxorubicin—prostate cancer	0.000103	0.000155	CcSEcCtD
Vigabatrin—GABBR1—Signaling by GPCR—PIK3CD—prostate cancer	0.000102	0.000616	CbGpPWpGaD
Vigabatrin—GABBR1—Signaling Pathways—VAV3—prostate cancer	0.000102	0.000615	CbGpPWpGaD
Vigabatrin—Gastrointestinal pain—Epirubicin—prostate cancer	0.000102	0.000154	CcSEcCtD
Vigabatrin—Dyspepsia—Doxorubicin—prostate cancer	0.000102	0.000153	CcSEcCtD
Vigabatrin—Vomiting—Prednisone—prostate cancer	0.000102	0.000153	CcSEcCtD
Vigabatrin—GABBR1—Signaling Pathways—TGFBR2—prostate cancer	0.000101	0.000606	CbGpPWpGaD
Vigabatrin—Rash—Prednisone—prostate cancer	0.000101	0.000151	CcSEcCtD
Vigabatrin—Dermatitis—Prednisone—prostate cancer	0.000101	0.000151	CcSEcCtD
Vigabatrin—Decreased appetite—Doxorubicin—prostate cancer	0.0001	0.000151	CcSEcCtD
Vigabatrin—Headache—Prednisone—prostate cancer	0.0001	0.00015	CcSEcCtD
Vigabatrin—Gastrointestinal disorder—Doxorubicin—prostate cancer	9.97e-05	0.00015	CcSEcCtD
Vigabatrin—Fatigue—Doxorubicin—prostate cancer	9.96e-05	0.00015	CcSEcCtD
Vigabatrin—Urticaria—Epirubicin—prostate cancer	9.92e-05	0.000149	CcSEcCtD
Vigabatrin—GABBR1—Signaling Pathways—ITPR1—prostate cancer	9.91e-05	0.000597	CbGpPWpGaD
Vigabatrin—Constipation—Doxorubicin—prostate cancer	9.88e-05	0.000149	CcSEcCtD
Vigabatrin—Pain—Doxorubicin—prostate cancer	9.88e-05	0.000149	CcSEcCtD
Vigabatrin—Body temperature increased—Epirubicin—prostate cancer	9.87e-05	0.000148	CcSEcCtD
Vigabatrin—Abdominal pain—Epirubicin—prostate cancer	9.87e-05	0.000148	CcSEcCtD
Vigabatrin—GABBR1—GPCR downstream signaling—PIK3CB—prostate cancer	9.81e-05	0.000591	CbGpPWpGaD
Vigabatrin—Feeling abnormal—Doxorubicin—prostate cancer	9.52e-05	0.000143	CcSEcCtD
Vigabatrin—Nausea—Prednisone—prostate cancer	9.48e-05	0.000143	CcSEcCtD
Vigabatrin—GABBR1—Signaling Pathways—IGF1R—prostate cancer	9.47e-05	0.000571	CbGpPWpGaD
Vigabatrin—Gastrointestinal pain—Doxorubicin—prostate cancer	9.45e-05	0.000142	CcSEcCtD
Vigabatrin—GABBR1—GPCR downstream signaling—CXCL8—prostate cancer	9.43e-05	0.000568	CbGpPWpGaD
Vigabatrin—GABBR1—Signaling by GPCR—JAK2—prostate cancer	9.38e-05	0.000565	CbGpPWpGaD
Vigabatrin—Hypersensitivity—Epirubicin—prostate cancer	9.2e-05	0.000138	CcSEcCtD
Vigabatrin—Urticaria—Doxorubicin—prostate cancer	9.18e-05	0.000138	CcSEcCtD
Vigabatrin—Body temperature increased—Doxorubicin—prostate cancer	9.13e-05	0.000137	CcSEcCtD
Vigabatrin—Abdominal pain—Doxorubicin—prostate cancer	9.13e-05	0.000137	CcSEcCtD
Vigabatrin—GABBR1—Signaling Pathways—LPL—prostate cancer	9.08e-05	0.000547	CbGpPWpGaD
Vigabatrin—GABBR1—GPCR downstream signaling—IL2—prostate cancer	9.01e-05	0.000543	CbGpPWpGaD
Vigabatrin—GABBR1—Signaling Pathways—PDGFRB—prostate cancer	9e-05	0.000542	CbGpPWpGaD
Vigabatrin—Asthenia—Epirubicin—prostate cancer	8.96e-05	0.000135	CcSEcCtD
Vigabatrin—GABBR1—Signaling by GPCR—PIK3CB—prostate cancer	8.91e-05	0.000537	CbGpPWpGaD
Vigabatrin—Pruritus—Epirubicin—prostate cancer	8.83e-05	0.000133	CcSEcCtD
Vigabatrin—GABBR1—Signaling Pathways—ITGB3—prostate cancer	8.77e-05	0.000528	CbGpPWpGaD
Vigabatrin—GABBR1—Signaling by GPCR—CXCL8—prostate cancer	8.56e-05	0.000516	CbGpPWpGaD
Vigabatrin—Diarrhoea—Epirubicin—prostate cancer	8.54e-05	0.000129	CcSEcCtD
Vigabatrin—Hypersensitivity—Doxorubicin—prostate cancer	8.51e-05	0.000128	CcSEcCtD
Vigabatrin—GABBR1—Signaling Pathways—ERBB3—prostate cancer	8.51e-05	0.000512	CbGpPWpGaD
Vigabatrin—GABBR1—Signaling Pathways—FGFR2—prostate cancer	8.49e-05	0.000512	CbGpPWpGaD
Vigabatrin—Asthenia—Doxorubicin—prostate cancer	8.29e-05	0.000125	CcSEcCtD
Vigabatrin—Dizziness—Epirubicin—prostate cancer	8.26e-05	0.000124	CcSEcCtD
Vigabatrin—GABBR1—Signaling by GPCR—IL2—prostate cancer	8.18e-05	0.000493	CbGpPWpGaD
Vigabatrin—Pruritus—Doxorubicin—prostate cancer	8.17e-05	0.000123	CcSEcCtD
Vigabatrin—GABBR1—Signaling Pathways—TERT—prostate cancer	8.15e-05	0.000491	CbGpPWpGaD
Vigabatrin—Vomiting—Epirubicin—prostate cancer	7.94e-05	0.000119	CcSEcCtD
Vigabatrin—Diarrhoea—Doxorubicin—prostate cancer	7.91e-05	0.000119	CcSEcCtD
Vigabatrin—Rash—Epirubicin—prostate cancer	7.87e-05	0.000118	CcSEcCtD
Vigabatrin—Dermatitis—Epirubicin—prostate cancer	7.87e-05	0.000118	CcSEcCtD
Vigabatrin—Headache—Epirubicin—prostate cancer	7.82e-05	0.000118	CcSEcCtD
Vigabatrin—GABBR1—Signaling Pathways—HIF1A—prostate cancer	7.8e-05	0.00047	CbGpPWpGaD
Vigabatrin—Dizziness—Doxorubicin—prostate cancer	7.64e-05	0.000115	CcSEcCtD
Vigabatrin—GABBR1—Signaling Pathways—LEP—prostate cancer	7.61e-05	0.000458	CbGpPWpGaD
Vigabatrin—GABBR1—Signaling Pathways—CAV1—prostate cancer	7.54e-05	0.000454	CbGpPWpGaD
Vigabatrin—GABBR1—Signaling Pathways—KDR—prostate cancer	7.46e-05	0.000449	CbGpPWpGaD
Vigabatrin—Nausea—Epirubicin—prostate cancer	7.42e-05	0.000112	CcSEcCtD
Vigabatrin—Vomiting—Doxorubicin—prostate cancer	7.35e-05	0.000111	CcSEcCtD
Vigabatrin—Rash—Doxorubicin—prostate cancer	7.28e-05	0.00011	CcSEcCtD
Vigabatrin—Dermatitis—Doxorubicin—prostate cancer	7.28e-05	0.000109	CcSEcCtD
Vigabatrin—GABBR1—Signaling Pathways—ESR1—prostate cancer	7.27e-05	0.000438	CbGpPWpGaD
Vigabatrin—Headache—Doxorubicin—prostate cancer	7.24e-05	0.000109	CcSEcCtD
Vigabatrin—GABBR1—Signaling Pathways—BAD—prostate cancer	7.09e-05	0.000427	CbGpPWpGaD
Vigabatrin—GABBR1—Signaling Pathways—APC—prostate cancer	6.87e-05	0.000414	CbGpPWpGaD
Vigabatrin—GABBR1—Signaling Pathways—PIK3CG—prostate cancer	6.87e-05	0.000414	CbGpPWpGaD
Vigabatrin—Nausea—Doxorubicin—prostate cancer	6.86e-05	0.000103	CcSEcCtD
Vigabatrin—GABBR1—Signaling Pathways—IRS1—prostate cancer	6.79e-05	0.000409	CbGpPWpGaD
Vigabatrin—GABBR1—Signaling Pathways—EGF—prostate cancer	6.79e-05	0.000409	CbGpPWpGaD
Vigabatrin—GABBR1—Signaling Pathways—GSK3B—prostate cancer	6.59e-05	0.000397	CbGpPWpGaD
Vigabatrin—GABBR1—Signaling Pathways—INS—prostate cancer	6.5e-05	0.000392	CbGpPWpGaD
Vigabatrin—GABBR1—Signaling Pathways—CREBBP—prostate cancer	6.37e-05	0.000384	CbGpPWpGaD
Vigabatrin—GABBR1—Signaling Pathways—IGF1—prostate cancer	6.29e-05	0.000379	CbGpPWpGaD
Vigabatrin—GABBR1—Signaling by GPCR—EGFR—prostate cancer	6.26e-05	0.000377	CbGpPWpGaD
Vigabatrin—GABBR1—Signaling Pathways—MAP2K1—prostate cancer	6.08e-05	0.000366	CbGpPWpGaD
Vigabatrin—GABBR1—Signaling Pathways—PIK3CD—prostate cancer	6.04e-05	0.000364	CbGpPWpGaD
Vigabatrin—GABBR1—GPCR downstream signaling—PIK3CA—prostate cancer	5.98e-05	0.00036	CbGpPWpGaD
Vigabatrin—GABBR1—Signaling Pathways—SERPINE1—prostate cancer	5.97e-05	0.00036	CbGpPWpGaD
Vigabatrin—GABBR1—Signaling by GPCR—KRAS—prostate cancer	5.91e-05	0.000356	CbGpPWpGaD
Vigabatrin—GABBR1—Signaling Pathways—FGF2—prostate cancer	5.78e-05	0.000348	CbGpPWpGaD
Vigabatrin—GABBR1—Signaling Pathways—NOS3—prostate cancer	5.7e-05	0.000343	CbGpPWpGaD
Vigabatrin—GABBR1—Signaling Pathways—JAK2—prostate cancer	5.54e-05	0.000334	CbGpPWpGaD
Vigabatrin—GABBR1—Signaling by GPCR—PIK3CA—prostate cancer	5.43e-05	0.000327	CbGpPWpGaD
Vigabatrin—GABBR1—Signaling Pathways—MDM2—prostate cancer	5.41e-05	0.000326	CbGpPWpGaD
Vigabatrin—GABBR1—Signaling Pathways—ERBB2—prostate cancer	5.33e-05	0.000321	CbGpPWpGaD
Vigabatrin—GABBR1—Signaling Pathways—PIK3CB—prostate cancer	5.26e-05	0.000317	CbGpPWpGaD
Vigabatrin—GABBR1—Signaling Pathways—CXCL8—prostate cancer	5.06e-05	0.000305	CbGpPWpGaD
Vigabatrin—GABBR1—Signaling Pathways—CDKN1B—prostate cancer	4.94e-05	0.000298	CbGpPWpGaD
Vigabatrin—GABBR1—GPCR downstream signaling—AKT1—prostate cancer	4.89e-05	0.000294	CbGpPWpGaD
Vigabatrin—GABBR1—Signaling Pathways—CASP3—prostate cancer	4.84e-05	0.000292	CbGpPWpGaD
Vigabatrin—GABBR1—Signaling Pathways—IL2—prostate cancer	4.83e-05	0.000291	CbGpPWpGaD
Vigabatrin—GABBR1—Signaling by GPCR—IL6—prostate cancer	4.81e-05	0.00029	CbGpPWpGaD
Vigabatrin—GABBR1—Signaling Pathways—CCND1—prostate cancer	4.71e-05	0.000284	CbGpPWpGaD
Vigabatrin—GABBR1—Signaling Pathways—CTNNB1—prostate cancer	4.67e-05	0.000281	CbGpPWpGaD
Vigabatrin—GABBR1—Signaling Pathways—MMP9—prostate cancer	4.57e-05	0.000276	CbGpPWpGaD
Vigabatrin—GABBR1—Signaling Pathways—CDKN1A—prostate cancer	4.56e-05	0.000275	CbGpPWpGaD
Vigabatrin—GABBR1—Signaling Pathways—PTEN—prostate cancer	4.55e-05	0.000274	CbGpPWpGaD
Vigabatrin—GABBR1—Signaling by GPCR—AKT1—prostate cancer	4.44e-05	0.000267	CbGpPWpGaD
Vigabatrin—GABBR1—Signaling Pathways—EP300—prostate cancer	4.34e-05	0.000261	CbGpPWpGaD
Vigabatrin—GABBR1—Signaling Pathways—SRC—prostate cancer	4.22e-05	0.000254	CbGpPWpGaD
Vigabatrin—GABBR1—Signaling Pathways—VEGFA—prostate cancer	4.11e-05	0.000247	CbGpPWpGaD
Vigabatrin—GABBR1—Signaling Pathways—STAT3—prostate cancer	4.07e-05	0.000245	CbGpPWpGaD
Vigabatrin—GABBR1—Signaling Pathways—MYC—prostate cancer	3.78e-05	0.000228	CbGpPWpGaD
Vigabatrin—GABBR1—Signaling Pathways—TGFB1—prostate cancer	3.77e-05	0.000227	CbGpPWpGaD
Vigabatrin—GABBR1—Signaling Pathways—EGFR—prostate cancer	3.7e-05	0.000223	CbGpPWpGaD
Vigabatrin—GABBR1—Signaling Pathways—KRAS—prostate cancer	3.49e-05	0.00021	CbGpPWpGaD
Vigabatrin—GABBR1—Signaling Pathways—PIK3CA—prostate cancer	3.21e-05	0.000193	CbGpPWpGaD
Vigabatrin—GABBR1—Signaling Pathways—TP53—prostate cancer	3.1e-05	0.000187	CbGpPWpGaD
Vigabatrin—GABBR1—Signaling Pathways—IL6—prostate cancer	2.84e-05	0.000171	CbGpPWpGaD
Vigabatrin—GABBR1—Signaling Pathways—AKT1—prostate cancer	2.62e-05	0.000158	CbGpPWpGaD
